Alan Thompson1, Gisela Kobelt2, Jenny Berg3, Daniela Capsa3, Jennifer Eriksson3, David Miller4. 1. UCL Institute of Neurology, University College London (UCL), London, UK. 2. European Health Economics, Mulhouse, France. 3. Mapi Group, Stockholm, Sweden. 4. Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London (UCL), London, UK.
Abstract
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in EUR (2015). RESULTS: A total of 779 patients (mean age = 57 years) participated; 72% were below retirement age and of these, 36% were employed. Employment was related to disease severity, and MS affected productivity at work for 84% of patients. Overall, 96% and 72% of the patients experienced fatigue and cognition as a problem. Mean utility and annual costs were 0.735 and 11,400GBP at Expanded Disability Status Scale (EDSS) = 0-3, 0.534 and 22,700GBP at EDSS = 4-6.5, and 0.135 and 36,500GBP at EDSS = 7-9. The mean cost of a relapse was estimated at 790GBP. CONCLUSION: This study illustrates the burden of MS on UK patients and provides current data on MS that are important for development of health policies.
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in EUR (2015). RESULTS: A total of 779 patients (mean age = 57 years) participated; 72% were below retirement age and of these, 36% were employed. Employment was related to disease severity, and MS affected productivity at work for 84% of patients. Overall, 96% and 72% of the patients experienced fatigue and cognition as a problem. Mean utility and annual costs were 0.735 and 11,400GBP at Expanded Disability Status Scale (EDSS) = 0-3, 0.534 and 22,700GBP at EDSS = 4-6.5, and 0.135 and 36,500GBP at EDSS = 7-9. The mean cost of a relapse was estimated at 790GBP. CONCLUSION: This study illustrates the burden of MS on UK patients and provides current data on MS that are important for development of health policies.
Entities:
Keywords:
HRQoL; Multiple sclerosis; United Kingdom; burden of illness; cognition; costs; fatigue
Authors: Timothy Spelman; William L Herring; Thibaut Dort; Yuanhui Zhang; Michael Tempest; Isobel Pearson; Ulrich Freudensprung; Carlos Acosta; Robert Hyde; Eva Havrdova; Dana Horakova; Maria Trojano; Giovanna De Luca; Alessandra Lugaresi; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Raed Alroughani; Eugenio Pucci; Franco Granella; Jeannette Lechner-Scott; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Csilla Rozsa; Cavit Boz; Raymond Hupperts; Vincent Van Pesch; Celia Oreja-Guevara; Anneke van der Walt; Vilija G Jokubaitis; Tomas Kalincik; Helmut Butzkueven Journal: Pharmacoeconomics Date: 2021-12-18 Impact factor: 4.981
Authors: Vivien Li; Baptiste Leurent; Frederik Barkhof; Marie Braisher; Fay Cafferty; Olga Ciccarelli; Arman Eshaghi; Emma Gray; Jennifer M Nicholas; Mahesh Parmar; Guy Peryer; Jenny Robertson; Nigel Stallard; James Wason; Jeremy Chataway Journal: Neurology Date: 2022-03-23 Impact factor: 11.800